Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network.

Autor: Sanz, A., Ayala, R., Hernández, G., Lopez, N., Gil-Alos, D., Gil, R., Colmenares, R., Carreño-Tarragona, G., Sánchez-Pina, J., Alonso, R. A., García-Barrio, N., Pérez-Rey, D., Meloni, L., Calbacho, M., Cruz-Rojo, J., Pedrera-Jiménez, M., Serrano-Balazote, P., de la Cruz, J., Martínez-López, J.
Předmět:
Zdroj: Blood Cancer Journal; Jun2022, Vol. 12 Issue 6, p1-4, 4p
Abstrakt: In the H12O cohort, 32 patients from each cohort were compared, with two deaths in the CML cohort and 5 in the non-oncology patients ( I p i = 0-23). The U.S. cohort also showed slightly better survival in non-oncologic patients but without statistical significance, 284 deaths out of 1852 CML patients versus 251 deaths out of 1852 non-oncologic patients, with an HR 1-095 (0-92-1-29), I p i = 0-295 (Supplementary Fig. In the U.S. cohorts, out of 5249 patients, 3380 (64-4%) CML patients developed a second malignancy, compared to only 902 (17.2%, I p i < 0-001) of the non-CML cohort (OR 8-72 with 95% CI (7-96, 9-55)). Thus, the analyses were run on four different patients cohorts to independently confirm our hypotheses: H12O, with around 1,000,000 patients; the EMEA Collaborative Network (EMEA), with 11,000,000 patients from 18 HCOs; the US Collaborative Network (US), with 73,000,000 patients from 47 HCOs, and the Global Collaborative Network (Global), with 90,000,000 patients from 75 HCOs. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz: